[go: up one dir, main page]

WO2007012968A2 - Forme dosifee stable d'un antidepresseur - Google Patents

Forme dosifee stable d'un antidepresseur Download PDF

Info

Publication number
WO2007012968A2
WO2007012968A2 PCT/IB2006/002158 IB2006002158W WO2007012968A2 WO 2007012968 A2 WO2007012968 A2 WO 2007012968A2 IB 2006002158 W IB2006002158 W IB 2006002158W WO 2007012968 A2 WO2007012968 A2 WO 2007012968A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
excipients
lactose
sodium
paroxetine hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002158
Other languages
English (en)
Other versions
WO2007012968A3 (fr
Inventor
Viswaprasad Varanasi
Haranatha Babu Balanagu
Hidaytulla Shamshuddin Aga
Kishor Dattatray Deo
Sivakumaran Meenakshisunderam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of WO2007012968A2 publication Critical patent/WO2007012968A2/fr
Publication of WO2007012968A3 publication Critical patent/WO2007012968A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a stable solid dosage form comprising an anti-depressant compound. More particularly, the present invention relates to a stable solid dosage form comprising paroxetine HCl hemihydrate prepared by wet granulation process comprising lactose.
  • Paroxetine disclosed in U.S Pat. No 4,007,196, is a serotonin re- uptake inhibitor useful for the treatment of psychiatric problems including depression, parkinson's disease, anxiety disorders, obsessive-compulsive disorders, panic disorder and post-traumatic stress disorder.
  • paroxetine is (-)-trans-3-[(l,3-benzodioxol-5- yloxy)methyl]-4-(4-fluorophenyl)piperidine and is commercially marketed under the trade name Paxil ® in the US and Seroxat ® in other countries by
  • paroxetine tablets contain paroxetine HCl hemihydrate as active ingredient and excipients such as dibasic calcium phosphate dihydrate, hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide.
  • the commercially available tablets are prepared by wet granulation using water as solvent, where in paroxetine HCl, dibasic calcium phosphate dihydrate, sodium starch glycolate/ magnesium stearate, and hydroxypropyl methyl cellulose were granulated with water and lubricated with sodium starch glycolate/ magnesium stearate and finally film coated with opadry.
  • the tablets prepared by wet granulation using water exhibited a color change i.e., formation of pink hue, which is highly undesirable.
  • US '944 patent teaches the preparation of paroxetine tablets using processes such as dry granulation and direct compression without using water. However, using these methods there is less flexibility in excipient selection and possibility of formation of hard tablets.
  • US 2003/0144324 describes oral pharmaceutical dosage form comprising paroxetine hydrochloride, a binder selected from the group consisting of povidone and copovidone, and filler that is HCl free or non- hygroscopic. It is disclosed that paroxetine hydrochloride tablets are particularly susceptible to becoming soft during storage, especially under accelerated aging conditions. In order to improve the hardness of the tablet povidone and copovidone are used as binders. It is further disclosed that an effective amount of povidone stabilizes the anhydrous form by preventing water molecules from incorporating into a paroxetine hydrochloride anhydrous crystal to yield a hemihydrate crystal.
  • US '324 does not disclose about the stabilization of paroxetine hydrochloride hemihydrate with povidone.
  • WO 2005/034954 describes composition of paroxetine prepared by wet granulation, using microcrystalline cellulose and other excipients.
  • WO 02/069969 discloses use of microcrystalline cellulose as a filler and copovidone as binder, and discloses that the microcrystalline cellulose is the perfect excipient.
  • the above prior art references discloses apart from dry granulation and direct compression, wet granulation process using water or organic solvent and using excipients such as microcrystalline cellulose, povidone, copovidone.
  • Microcrystalline cellulose, povidone and copovidone being hygroscopic can absorb varying amounts of moisture at low relative humidities. Further, microcrystalline cellulose is an insoluble excipient where as lactose is a water-soluble excipient and is preferred over microcrystalline cellulose.
  • lactose as diluent provided tablets which have an excellent hardness and breaking load, with release properties similar to the marketed dosage form. Further, the problem of pink hue development as seen in the Paxil® tablets prepared by wet granulation process is surprisingly not observed.
  • the main objective of present invention is to provide a stable solid dosage form of paroxetine hydrochloride hemihydrate.
  • Yet another objective of the present invention is to provide a solid dosage form of paroxetine hydrochloride hemihydrate in such a way that it will comply with the reference product in terms of in vivo parameters like bioequivalence and in vitro parameters like dissolution, disintegration, and etc.
  • Yet another objective of the present invention is to provide process for preparing stable solid dosage form of paroxetine.
  • a stable solid dosage form comprising paroxetine hydrochloride hemihydrate, lactose, and one or more pharmaceutically acceptable excipients prepared by wet granulation process, wherein the excipients are not microcrystalline cellulose, povidone, and copovidone.
  • the present invention provides stable dosage form of paroxetine hydrochloride hemihydrate, which does not develop pink hue upon storage.
  • the excipients used are selected from diluents, binders, disintegrants, and lubricants.
  • the wet granulation is always preferred over dry or direct compression, since uniform distribution of the active substance within the bulk granulates is achieved without difficulty and also flexibility in selection of excipients.
  • the stable dosage form of paroxetine hydrochloride hemihydrate comprises excipients selected from about 70% to about 95% of diluent, about 1.5% to about 5% of disintegrant, about 2.5% to about 7.5% of binder and about 0.5% to about 3% of lubricant wherein the tablet is prepared by wet granulation using, aqueous, nonaqueous solvents or mixture thereof.
  • Suitable diluents of the present invention include lactose, sucrose, calcium phosphate-dibasic, calcium silicate, starch, polyols such as mannitol, sorbitol, xylitol, maltitol, or combination thereof.
  • Suitable disintegrating agents used in accordance with the present invention are selected from crosscarmellose sodium, sodium starch glycolate, sodium carboxymethyl cellulose, hydroxypropyl cellulose, alginic acid, alginates, polacrilin potassium, and the like or combination thereof.
  • Suitable binders of the present invention include hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, gelatin, alginates, methylcellulose or starch.
  • Suitable lubricants of the present invention include sodium stearyl fumarate, magnesium stearate, hydrogenated vegetable oil, stearic acid, calcium stearate, glyceryl behenate, sodium lauryl sulfate, talc and the like.
  • paroxetine hydrochloride hemihydrate compositions of the present invention are stable and do not substantially loose its hardness after storage at a temperature of about 80 0 C and a relative humidity of at least about 75% for at least about 24 hours.
  • the dosage form of the present invention includes tablets, capsules and powder for oral suspension.
  • the tablets may be uncoated or optionally coated with film forming materials such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium lauryl sulfate, talc, colloidal silica, sodium stearyl fumarate and the like.
  • a process for preparing stable solid dosage form comprising paroxetine hydrochloride hemihydrate, lactose, and one or more pharmaceutically acceptable excipients prepared by wet granulation process, wherein the excipients are not microcrystalline cellulose, povidone, and copovidone, comprises the steps of: i) blending paroxetine hydrochloride hemihydrate with lactose, filler, and disintegrant, ii) granulating the blend of step (i) using aqueous or non-aqueous solvent or mixture thereof, iii) drying the granules obtained in step (ii) at 40 0 C, iv) blending the dried granules with extragranular excipients, v) lubricating the blended granules of step (iv) and vi) compressing the lubricated blend into tablets or filled into capsules.
  • aqueous or non-aqueous solvents used according to the present invention are selected from water, isopropyl alcohol, ethanol, acetone, methylene chloride and the like or mixture thereof.
  • the present invention also provides method of treating depression, mixed anxiety and depression, obsessive compulsive disorders, panic disorder, obesity, senile dementia, migraine, bulimia, anorexia, social phobia and the depression arising from premenstrual tension and adolescence by administering the stable solid dosage form of the present invention.
  • paroxetine hydrochloride, dibasic calcium phosphate, lactose, and sodium starch glycolate were sifted and blended, ii) granulated the blended material of step (i) with water or water/ethanol mixture and dried the granulated mass at 40 0 C, iii) dried granules were blended with extragranular dibasic calcium phosphate and sodium starch glycolate for 15 min, iv) lubricated the blended granules of step (iv) with magnesium stearate for 5 min., v) compressed the lubricated blend into tablets, and vi) finally the tablets were coated with film forming materials.
  • paroxetine hydrochloride, dibasic calcium phosphate, lactose, and sodium starch glycolate were sifted and blended
  • binder solution of low viscosity hydroxypropyl cellulose in water or water/ethanol mixture was prepared
  • granulated the blended material of step (i) with binder solution of step (ii) and dried the granulated mass at 4O 0 C iv) dried granules were blended with extragranular dibasic calcium phosphate and sodium starch glycolate for 15 min
  • vii) finally the tablets were coated with film forming materials.
  • paroxetine hydrochloride, dibasic calcium phosphate, lactose, and sodium starch glycolate were sifted and blended, ii) granulated the blended material of step (i) with water and dried the granulated mass at.40 0 C, iii) dried granules were blended with extragranular dibasic calcium phosphate and sodium starch glycolate for 15 min, iv) lubricated the blended granules of step (iv) with magnesium stearate for 5 min., v) compressed the lubricated blend into tablets, and
  • Table 1 given below shows the dissolution profile of paroxetine tablets carried out in Simulated gastric fluid without enzymes as medium according to the procedure described in the USP, Apparatus USP 11/900 ml, Paddle, @ 60 rpm speed.
  • the release profile (% of drug released in minutes) is given in table 1.
  • Stability Data Tablets of examples 5 and 6 were stored at 40°C/75%RH, for one, two, three and six months and then tested by an HPLC method to determine the amount of paroxetine hydrochloride hemihydrate. The data is given in table 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention se rapporte à une forme dosifiée stable renfermant un composé antidépresseur. Cette invention porte en particulier sur une forme dosifiée solide stable comprenant un semi-hydrate d'hydrochlorure de paroxétine préparée par un procédé de granulation par voie humide utilisant de la lactose.
PCT/IB2006/002158 2005-07-29 2006-07-25 Forme dosifee stable d'un antidepresseur Ceased WO2007012968A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1039CH2005 2005-07-29
IN1039/CHE/2005 2005-07-29

Publications (2)

Publication Number Publication Date
WO2007012968A2 true WO2007012968A2 (fr) 2007-02-01
WO2007012968A3 WO2007012968A3 (fr) 2007-05-31

Family

ID=37683713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002158 Ceased WO2007012968A2 (fr) 2005-07-29 2006-07-25 Forme dosifee stable d'un antidepresseur

Country Status (1)

Country Link
WO (1) WO2007012968A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525966A (zh) * 2010-12-13 2012-07-04 江苏万全特创医药生物技术有限公司 一种含有帕罗西汀的片剂及其制备方法
CN109771381A (zh) * 2017-11-13 2019-05-21 北京万生药业有限责任公司 一种帕罗西汀药物制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057151A2 (fr) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. Formulation pharmaceutique stable d'hydrochlorure de paroxetine anhydre et procede de preparation
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
WO2005034954A2 (fr) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Compositions pharmaceutiques de paroxetine
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525966A (zh) * 2010-12-13 2012-07-04 江苏万全特创医药生物技术有限公司 一种含有帕罗西汀的片剂及其制备方法
CN109771381A (zh) * 2017-11-13 2019-05-21 北京万生药业有限责任公司 一种帕罗西汀药物制剂

Also Published As

Publication number Publication date
WO2007012968A3 (fr) 2007-05-31

Similar Documents

Publication Publication Date Title
EP3606511B1 (fr) Composition pharmaceutique contenant du lenvatinib mesylate
EP3501506B1 (fr) Composition de comprimé pharmaceutique comprenant du brexpiprazole
EP3860606B1 (fr) Composition pharmaceutique comprenant esylate ou tosylate de lenvatinib
JP7724776B2 (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
AU2009243734B2 (en) Granulate comprising escitalopram oxalate
EP2134325A2 (fr) Formes posologiques solides stables d'un antidépresseur
RU2463039C2 (ru) Эсциталопрам и твердая фармацевтическая композиция, его содержащая
AU2016268477B2 (en) Pharmaceutical compositions
WO2007012968A2 (fr) Forme dosifee stable d'un antidepresseur
EP4424303A1 (fr) Composition de lenvatinib présentant une biodisponibilité améliorée
CZ2011872A3 (cs) Farmaceutická formulace prasugrelu hydrobromidu
US20100178342A1 (en) Solid Pharmaceutical Preparation
WO2024126409A1 (fr) Composition pharmaceutique contenant du siponimod
US20250134841A1 (en) Pharmaceutical composition of bempedoic acid
HUP0600839A2 (en) Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof
CA2452357A1 (fr) Formulation medicamenteuse contenant un antagoniste du ltb4
JP2023551597A (ja) フタラジノン誘導体を含む薬剤学的組成物
JP2025036080A (ja) グアンファシンを含む医薬組成物及びその製造方法
KR20240155526A (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
RO135833A2 (ro) Compoziţii farmaceutice care conţin pramiracetam hidrat, procedeu de obţinere a acestora şi utilizările lor
WO2006103506A1 (fr) Compositions pharmaceutiques contenant de la sertraline, et methode de preparation desdites compositions
ZA200602999B (en) Solid pharmaceutical preparation form
WO2006008567A1 (fr) Compositions pharmaceutiques a base de composes piperidinoalcanols

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06795217

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06795217

Country of ref document: EP

Kind code of ref document: A2